期刊文献+

氯吡格雷对人胃黏膜上皮细胞紧密连接蛋白表达的影响 被引量:1

原文传递
导出
摘要 氯吡格雷治疗心脑血管疾病的疗效优于阿司匹林,但其对胃肠道的损伤引起了广泛关注。紧密连接蛋白是细胞间连接的一个重要形式,由Claudin蛋白、Oeeludin蛋白、JAM、ZOs等结构蛋白及各类连接蛋白分子组成,Occludin蛋白是最先被分离出来的紧密连接蛋白跨膜蛋白,也是紧密连接蛋白中最重要的结构蛋白。免疫电子显微镜示,Occludin蛋白定位于紧密连接蛋白上,不仅能通过外环以拉链式结合而产生严密的细胞旁封闭,还能与不同分子结合,参与紧密连接蛋白形成的信号调节。
出处 《中华消化杂志》 CAS CSCD 北大核心 2012年第7期479-481,共3页 Chinese Journal of Digestion
基金 南京市医学科技发展项目(YKKl0107)
  • 相关文献

参考文献4

  • 1孙沂,樊宏伟,王书奎,何帮顺,张振玉.氯吡格雷对人胃黏膜上皮细胞株GES-1增殖作用的影响[J].世界华人消化杂志,2010,18(4):329-334. 被引量:11
  • 2McQuaid KR, Laine I.. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med, 2006,119 : 624-638.
  • 3Bhatt DL, Scheiman J, Abraham NS,et a. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol, 2008,52: 1502-1517.
  • 4Yang R, Harada T, Li J, et al. Bile modulates intestinal epithelial barrier function via an extraeellular signal related kinase 1/2 dependent meehanism. Intensive Care Med, 2005,3 l 709-717.

二级参考文献21

  • 1Durand-Zaleski I, Bertrand M. The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study. Pharmacoeconomics 2004; 22 Suppl 4: 19-27.
  • 2Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
  • 3Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
  • 4Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-2420.
  • 5Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-944.
  • 6Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A, Mamdani MM. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-718.
  • 7Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006; 4: 2508-2509.
  • 8Fontana P, Senouf D, Mach F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res 2008; 121: 463-468.
  • 9Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, Salazar DE, Winters KJ. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008; 48: 475-484.
  • 10Cavusoglu E, Cheng J, Bhatt R, Kunamneni PB, Marmur JD, Eng C. Clopidogrel in the management of ischemic heart disease. Heart Dis 2003; 5: 144-152.

共引文献10

同被引文献21

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部